Immunotherapy has emerged as a transformative domain within oncology and a variety of other medical fields, demonstrating its potential through the use of immune checkpoint inhibitors, adoptive cell therapies, and monoclonal antibodies. These strategies have significantly improved cancer treatment outcomes and broadened therapeutic horizons. Nonetheless, the clinical application of numerous therapeutic and diagnostic targets remains limited, reducing the translational impact of molecular biology advances. NSG-based technologies focusing on B and T cell receptor repertoires have enabled the development of next-generation immunotherapies such as CAR therapies, engineered antibodies, and bispecific antibodies, enhancing treatment options across infectious diseases, autoimmune disorders, and cancers.
This Research Topic aims to provide a comprehensive summary of current methodologies used in the creation and development of pertinent immunotherapies. It seeks to present an up-to-date exploration of the rapidly evolving fields of antibody development and immune receptor repertoire analysis, emphasizing their clinical relevance across various disease states, including autoimmune and infectious diseases, and particularly cancer.
To expand the boundaries of molecular immunology and immunotherapy development, this Research Topic encourages contributions that explore diverse aspects, including but not limited to:
o Novel techniques for discovering and crafting antibodies and receptor-specific molecules (ScFv, VHH)
o Innovative methods for identifying antigens associated with antibodies and TCRs
o Creation of databases cataloging T- and B-cell receptor repertoires from individuals and patients exposed to specific conditions
o Preclinical studies validating the efficacy of targeted immunotherapies and diagnostics, such as CAR therapies, ADCs, BiTEs, and companion diagnostics
With the adoption of advanced tools like NGS in receptor complexity analysis and screening, the future of immunotherapy looks promising, potentially ushering in a new era of enhanced specificity and efficacy in treatment across multiple diseases. Contributions ranging from original research articles to comprehensive reviews are welcomed to deepen understanding and push the boundaries of this exciting field.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Immunotherapy has emerged as a transformative domain within oncology and a variety of other medical fields, demonstrating its potential through the use of immune checkpoint inhibitors, adoptive cell therapies, and monoclonal antibodies. These strategies have significantly improved cancer treatment outcomes and broadened therapeutic horizons. Nonetheless, the clinical application of numerous therapeutic and diagnostic targets remains limited, reducing the translational impact of molecular biology advances. NSG-based technologies focusing on B and T cell receptor repertoires have enabled the development of next-generation immunotherapies such as CAR therapies, engineered antibodies, and bispecific antibodies, enhancing treatment options across infectious diseases, autoimmune disorders, and cancers.
This Research Topic aims to provide a comprehensive summary of current methodologies used in the creation and development of pertinent immunotherapies. It seeks to present an up-to-date exploration of the rapidly evolving fields of antibody development and immune receptor repertoire analysis, emphasizing their clinical relevance across various disease states, including autoimmune and infectious diseases, and particularly cancer.
To expand the boundaries of molecular immunology and immunotherapy development, this Research Topic encourages contributions that explore diverse aspects, including but not limited to:
o Novel techniques for discovering and crafting antibodies and receptor-specific molecules (ScFv, VHH)
o Innovative methods for identifying antigens associated with antibodies and TCRs
o Creation of databases cataloging T- and B-cell receptor repertoires from individuals and patients exposed to specific conditions
o Preclinical studies validating the efficacy of targeted immunotherapies and diagnostics, such as CAR therapies, ADCs, BiTEs, and companion diagnostics
With the adoption of advanced tools like NGS in receptor complexity analysis and screening, the future of immunotherapy looks promising, potentially ushering in a new era of enhanced specificity and efficacy in treatment across multiple diseases. Contributions ranging from original research articles to comprehensive reviews are welcomed to deepen understanding and push the boundaries of this exciting field.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.